Compare SQNS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | CUE |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 49.6M |
| IPO Year | 2011 | 2018 |
| Metric | SQNS | CUE |
|---|---|---|
| Price | $4.97 | $0.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $21.33 | $3.00 |
| AVG Volume (30 Days) | 152.9K | ★ 1.7M |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,534,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.61 | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.20 | N/A |
| 52 Week Low | $4.44 | $0.23 |
| 52 Week High | $58.30 | $1.75 |
| Indicator | SQNS | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 43.96 |
| Support Level | $4.44 | $0.23 |
| Resistance Level | $4.88 | $0.44 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 42.07 | 57.32 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.